The majority of women with early-stage breast cancer and a mid-range score on a 21-tumor gene expression test see no added benefit from undergoing chemotherapy alongside hormone therapy during treatment, researchers reported this month at the American Society of Clinical Oncology’s annual meeting in Chicago, Illinois.